AMN Healthcare Services (NYSE:AMN) Delivers Strong Q2 CY2026 Numbers, Stock Jumps 11.5%

AMN Healthcare Services (NYSE:AMN) reported Q2 CY2026 revenue of $673.2 million, up 2.3% year on year, beating Wall Street expectations. Next-quarter revenue guidance was $647.5 million at the midpoint, about 4.7% above consensus. Non-GAAP EPS was $0.77, above estimates, and the stock rose 11.5% to $34.29. Analysts expect full-year EPS to fall to $0.88.

Original reporting
Published Aug 6, 2026, 11:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 11:38 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AMN Healthcare Services (NYSE:AMN) Delivers Strong Q2 CY2026 Numbers, Stock Jumps 11.5% — source image
Decision brief

The 30-second read

$AMNBullishMed
01

Why it matters

The article frames the quarter as a beat on revenue and adjusted EPS plus better-than-expected next-quarter revenue guidance, while also highlighting weak longer-term growth trends and a large expected EPS decline over the next 12 months.

02

Market read

AMN’s earnings and guidance drove an 11.5% stock jump, but the forward EPS outlook described in the article introduces a fundamental overhang.

03

What to watch

Traveler count is down YoY while revenue grew, suggesting pricing rather than volume; traders should scrutinize whether guidance durability depends on temporary staffing rates.

Relevance 8/10Novelty 7/10Timing: post-results, same-day reaction after Q2 CY2026 print

Background

AMN Healthcare Services provides healthcare workforce solutions and reports traveler-on-assignment metrics alongside financial results.

Company-level read

Ticker impact

$AMNBullishMedium confidence
Context

AMN reported Q2 CY2026 revenue of $673.2M (+2.3% YoY) and adjusted EPS of $0.77, beating consensus, and guided next-quarter revenue above expectations.

Expected impact

Bullish bias for the next few sessions, with elevated volatility as traders reconcile beat-and-guide versus expected 12-month EPS contraction.

Evidence & confidence

The article cites a same-day stock jump of 11.5% plus beat on EPS and revenue, but also states sell-side expects full-year EPS to fall 74.7% from $3.48 to $0.88, which can cap follow-through.

Market effects

Healthcare staffing demand and pricing dynamics may look steadier if AMN’s traveler trends and margin expansion persist.

No specific regional impact described beyond US healthcare staffing operations.

Limited global spillover; story is company-specific within US staffing.

Counterpoint

The beat may be partly price-driven and margin may not sustain, especially with the article’s expectation of a steep full-year EPS drop.

Key entities

  • AMN Healthcare Services

    NYSE-listed healthcare staffing firm reporting Q2 CY2026 results and next-quarter revenue guidance.

Related articles

$AMNMed

AMN Healthcare Adds AI Interpreting as Prices Squeezed

AMN Healthcare reported Q2 2026 language services revenue of $69.6m, down 8% YoY due to pricing pressure. Overall revenue rose 2% to $673.2m, with net income at $21.2m. The company acquired Jaide Health for AI interpreting services and expects Q3 revenue of $640m-$655m.

$AMNMedAI 9/10

AMN Healthcare (AMN) Q2 2026 Earnings Call Transcript

AMN Healthcare reported Q2 2026 revenue of $673 million, up 2% year over year and 6% above the top end of guidance, with adjusted EPS of $0.77. Adjusted EBITDA was $73 million (10.9% margin) after $27 million in nonrecurring billing true-ups. Q3 revenue guidance is $640 million to $655 million. AMN also authorized share repurchases and acquired Jaide Health and ESSENTIAL.

$AMNMedAI 8/10

5 Revealing Analyst Questions From AMN Healthcare Services’s Q2 Earnings Call

AMN Healthcare Services reported Q2 revenue of $673.2 million, above analysts’ $628.2 million estimate, and adjusted EPS of $0.77 versus $0.19. Management attributed results to strong Nurse and Allied Solutions demand, including travel nurse and allied volumes, plus higher labor disruption revenue and improved search and international execution. Q3 revenue guidance midpoint was $647.5 million.

$AMNHighAI 9/10

AMN HEALTHCARE ANNOUNCES SECOND QUARTER 2026 RESULTS

AMN Healthcare Services (NYSE: AMN) reported Q2 2026 revenue of $673 million, up 2% year over year, and adjusted EBITDA of $73 million. GAAP net income was $21 million, or $0.53/share, and adjusted EPS was $0.77. The company said results exceeded guidance, citing travel nurse and allied growth, 27% search revenue growth, and acquisitions expanding AI and leadership offerings. Q3 revenue is expected 1-3% higher.

$LULUMed

JPMorgan resets Lululemon stock price target by 38%

JPMorgan cut Lululemon's (LULU) price target by 38% to $95, citing weak Q2 results and lower guidance. Revenue fell 4% to $2.4B, with North America and China sales declining. LULU stock is down 80% from highs. Boss maintained a 'Neutral' rating, noting challenges and high marketing costs.

$SUPVMed

Supervielle (SUPV) Swings Back To Profit As Layoffs Reshape The Bank

Grupo Supervielle (SUPV) reported a net income of AR$12.8 billion for Q2, reversing a prior loss, driven by a 17% workforce reduction and cost-cutting. Adjusted net income was AR$36.2 billion, with an adjusted ROAE of 12.4%. Lending metrics improved, with net interest income up 13.1% and NPL ratio at 5.5%. However, the bank posted a net loss of AR$5.4 billion for H1, with ROAA at 0.6% for Q2 and -0.1% for H1.